BIOTECH CATALYST AI SCANNER — September WK4
BIOSTOCKINFO / CATALYST SCANNER
Scan date 2026-09-19 · 10 featured · 10 watchlist
The tape
XBI closed September 18 at 156.72: +0.3% over one week, -7.6% over one month, +11.4% over three months, +29.0% year to date, and -7.6% from its 52-week high of 169.55. In contrast, the S&P 500 (SPY) closed at 761.69: -0.3% over one week, -1.0% over one month, +2.0% over three months, +11.5% year to date, and -2.1% from its 52-week high of 777.88. The modest weekly divergence reflects sector-specific resilience rather than broad market momentum.
Breadth remains compressed, with 30% of the 5,915 tracked US small and mid caps closing above their 20-day average on September 18. This narrow foundation suggests that clinical catalysts must deliver clean, unambiguous efficacy to overcome defensive positioning across developmental biotech.
The US 10-year Treasury yield stood at 5.00% on September 18: +2 bp over one week, +55 bp over three months, near its 52-week high of 5.01% against a low of 3.95%.
This week at a glance
| TICKER | CATALYST | DATE | RANK |
|---|---|---|---|
| FTH | Topline Data, PIKTOR | year-end 2026 | 84 |
| IONS | PDUFA, bepirovirsen | Oct 26, 2026 | 83 |
| FBIO | Topline Data, Triplex | late 2026 | 82 |
| AGIO | PDUFA, PYRUKYND (mitapivat) | Nov 1, 2026 | 82 |
| AKBA | Topline Data, Vafseo (vadadustat) | in Q4 2026 | 80 |
| RAPP | Topline Data, RAP-219 | October 2026 | 80 |
| EIKN | Conference Presentation, EIK1003 | Oct 23, 2026 | 80 |
| PALI | Conference Presentation, PALI-2108 | Oct 9–Oct 14, 2026 | 80 |
| IMCR | Topline Data, KIMMTRAK (tebentafusp) | as early as the end of 2026 | 80 |
| NAMS | Topline Data, obicetrapib | by year end 2026 | 80 |
Top 10 names by scanner score, highest first. Rank is the scanner’s score out of 100.
Featured
FTH — Faeth Therapeutics
CATALYST year-end 2026Data readout | RANK 84 | PRICE $34.50 +7% 20d |
| CAP $892M (26M sh) | CASH $179M ~63 mo | |
Faeth Therapeutics expects topline data from its Phase 2 Study FTH-PIK-201 evaluating PIKTOR in second-line advanced endometrial cancer by year-end 2026 (company's words; quarter-level precision). The readout determines whether simultaneous multi-node inhibition delivers sufficient single-agent activity in advanced gynecologic tumors.
Company. Faeth Therapeutics is a clinical-stage oncology company developing all-oral multi-node inhibitors of the PI3K/AKT/mTOR pathway. Following its combination with Sensei Biotherapeutics, it has no commercial revenue, with an additional Phase 1b/2 breast cancer trial reading out in 2027.
Science & competition. PIKTOR simultaneously blocks PI3K, AKT, and mTOR signaling nodes to prevent cancer cells from activating bypass resistance pathways. Rivals include Pembrolizumab (Merck, FDA-approved) and Lenvatinib (Eisai, FDA-approved). Frontline treatment is carboplatin plus paclitaxel with an anti–PD-1 inhibitor, followed by maintenance immunotherapy.
Competition sources
Sources: moffitt.org · fda.gov · fda.gov · clinicaltrials.eu · fda.gov · daiichisankyo.us · daiichisankyo.us · healthtree.org
Why it could work. Simultaneous pathway blockade conceptually overcomes rapid bypass resistance, backed by a prior Phase 2 trial meeting its primary endpoint in platinum-resistant ovarian cancer.
Why it could fail. Broad pathway inhibition risks severe class toxicities like hyperglycemia and rash, while historical endometrial efficacy rested on only six evaluable patients.
IONS — Ionis Pharmaceuticals
CATALYST Oct 26, 2026Regulatory | RANK 83 | PRICE $44.44 -24% 20d |
| CAP $7.4B (166M sh) | CASH $2.0B ~48 mo | |
The FDA has granted Priority Review for bepirovirsen in chronic hepatitis B with a PDUFA action date of Oct 26, 2026. BTD, FTD, Priority Review**** The agency's decision decides whether Ionis and partner GSK establish the first finite-duration functional cure therapy in chronic hepatitis B.
Company. Ionis Pharmaceuticals commercializes and develops RNA-targeted antisense medicines for neurological and cardiometabolic indications. Commercial revenue includes independent launch ZANVASTRO alongside royalties from partners Novartis, AstraZeneca, GSK, Roche, and Biogen, while targeting cash-flow breakeven in 2028.
Science & competition. Bepirovirsen is an antisense oligonucleotide designed to bind hepatitis B viral RNA, halting replication and reducing surface antigen to restore immune function. Rivals include AHB-137 (AusperBio, Phase 3 (China) / Phase 2 (Global)) and GST-HG141 (Fujian Akeylink / Cosunter, Phase 3). The standard of care is long-term oral nucleos(t)ide analogues or finite 48-week pegylated interferon alfa-2a.
Competition sources
Sources: umn.edu · biochempeg.com · touchinfectiousdiseases.com · ionis.com · clinicaltrials.gov · oligotherapeutics.org · emjreviews.com
Why it could work. Phase 2b data demonstrated unprecedented durable clearance of viral surface antigen in 9% to 10% of patients receiving stable antiviral therapy.
Why it could fail. Modest absolute cure rates and potential immune-mediated liver enzyme flares could limit labeling, leaving physicians on cheap generic antivirals.
Recent development. On August 24, 2026, Japan's Ministry of Health, Labour and Welfare approved Hibsago (bepirovirsen) as a functional cure for chronic hepatitis B in adult patients (ionis.com).
FBIO — Fortress Biotech
CATALYST late 2026Data readout | RANK 82 | PRICE $2.51 -9% 20d |
| CAP $84M (33M sh) | CASH $197M no net burn | |
Fortress Biotech expects topline data from its fully enrolled Phase 2 trial of Triplex for the prevention and control of CMV in adults co-infected with HIV and CMV in late 2026 (company's words; quarter-level precision). The readout determines whether a therapeutic vaccine can suppress cytomegalovirus reactivation without continuous antiviral toxicity.
Company. Fortress Biotech acquires and develops clinical-stage assets, generating product revenue alongside equity holdings and royalty streams. Key programs include Triplex and dotinurad, alongside advancing subsidiary programs such as MB-109 in recurrent glioblastoma.
Science & competition. Triplex uses an engineered viral vector to stimulate specialized T-cell immune responses against cytomegalovirus, preventing reactivation in immunocompromised individuals. Rivals include Valganciclovir (Valcyte) (Roche / Genentech, FDA-approved (2001) for induction and maintenance of CMV retinitis in AIDS) and Ganciclovir (Cytovene) (Roche / Genentech, FDA-approved (1989 [IV]) for treatment and maintenance of CMV retinitis in immunocompromised patients, including individ). The standard of care is prompt antiretroviral therapy combined with oral valganciclovir if acute treatment is required.
Competition sources
Sources: nih.gov · i-base.info · hopkinsguides.com · gilead.com · hiv.gov · clinicaltrialsarena.com · oup.com · hiv.gov
Why it could work. Targeted T-cell activation aims to restore natural host immune control, potentially reducing viral shedding and systemic inflammation without daily small-molecule toxicities.
Why it could fail. SEC filings omit sample size and placebo details, and anti-vector antibodies could undermine durability or yield inconclusive viral load suppression.
AGIO — Agios Pharmaceuticals
CATALYST Nov 1, 2026Regulatory | RANK 82 | PRICE $33.07 -2% 20d |
| CAP $2.0B (60M sh) | CASH $920M ~31 mo | |
The FDA has set a PDUFA goal date of Nov 1, 2026, for the supplemental New Drug Application of mitapivat in sickle cell disease under accelerated review. The decision decides whether Agios expands its oral pyruvate kinase activator into non-malignant hematology following the market exit of competing therapies.
Company. Agios Pharmaceuticals commercializes therapies for rare hematologic conditions, marketing AQVESME in thalassemia. It generates product revenue while advancing a clinical pipeline that includes mitapivat in sickle cell disease, AG-181 in PKU, and AG-236 in polycythemia vera.
Science & competition. Mitapivat is an oral small-molecule pyruvate kinase activator that boosts red blood cell adenosine triphosphate and decreases 2,3-DPG to inhibit sickling. Rivals include Hydroxyurea (Bristol Myers Squibb / Addmedica, FDA-approved (1998 for adults; 2017 for pediatrics)) and Etavopivat (Novo Nordisk, Phase 3 completed). The standard of care is oral hydroxyurea supported by hydration, pain management, and red blood cell transfusions.
Competition sources
Sources: vcuhealth.org · fiercebiotech.com · medcentral.com · yalemedicine.org · clinicaltrialsarena.com · delveinsight.com · openpr.com · hcplive.com
Why it could work. In the Phase 3 RISE UP trial, mitapivat significantly increased hemoglobin response and reduced annualized vaso-occlusive crises in sickle cell patients.
Why it could fail. Regulators may demand hard clinical outcomes over surrogate hemoglobin increases or impose restrictive safety monitoring on accelerated labeling.
Filing flag. Agios announced it will not advance tebapivat in lower-risk myelodysplastic syndromes or sickle cell disease following Phase 2b and Phase 2 results.
AKBA — Akebia Therapeutics
CATALYST in Q4 2026Data readout | RANK 80 | PRICE $0.92 -0% 20d |
| CAP $254M (277M sh) | CASH $156M no net burn | |
Akebia expects topline data from the Phase 3b VOCAL trial evaluating three-times-weekly dosing of Vafseo (vadadustat) in anemia due to CKD in dialysis in Q4 2026 (company's words; quarter-level precision). The trial decides whether intermittent clinic-aligned administration can match approved once-daily dosing regimens.
Company. Akebia Therapeutics is a commercial biopharmaceutical company marketing Vafseo for dialysis-related chronic kidney disease anemia. Commercial product revenue funds operations alongside mid-stage pipeline assets ebribafusp for glomerular kidney diseases and praliciguat.
Science & competition. Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that mimics the physiological response to hypoxia to stimulate endogenous erythropoietin production. Rivals include Jesduvroq (daprodustat) (GSK, FDA-approved (February 2023)) and Aranesp (darbepoetin alfa) (Amgen, FDA-approved (2001)). The standard of care is injectable erythropoiesis-stimulating agents administered alongside intravenous iron supplementation.
Competition sources
Sources: haaselab.org · ashpublications.org · spherixglobalinsights.com · fiercepharma.com · fda.gov · kidneynews.org · clinicaltrials.gov · nih.gov
Why it could work. Synchronizing dosing with routine thrice-weekly dialysis clinic schedules eliminates patient home compliance hurdles, building on positive interim safety outcomes in the 2,116-patient VOICE trial.
Why it could fail. Intermittent dosing requires higher single doses, risking peak-concentration blood pressure spikes, thrombosis, or inadequate hemoglobin maintenance.
Recent development. On September 14, 2026, Akebia announced the first patient dosed in its Phase 2 open-label basket trial of ebribafusp in rare complement-mediated kidney diseases (akebia.com).
RAPP — Rapport Therapeutics
CATALYST October 2026Data readout | RANK 80 | PRICE $40.45 -15% 20d |
| CAP $1.9B (48M sh) | CASH $415M ~51 mo | |
Rapport Therapeutics expects topline results from its Phase 2 proof-of-concept trial evaluating RAP-219 in bipolar mania in October 2026 (company's words; month-level precision). The readout decides whether selective neuro-receptor modulation can expand outside core focal onset epilepsy programs.
Company. Rapport Therapeutics develops precision small-molecule medicines for central nervous system disorders. It has no commercial revenue, advancing lead asset RAP-219 across focal epilepsy Phase 3 FOCUS trials, acute bipolar mania, and long-acting injectable formulations.
Science & competition. RAP-219 is an oral negative allosteric modulator targeting AMPA glutamate receptors associated with TARPgamma8, dampening localized cortical hyperexcitability. Rivals include Lithium (Generic / Various (originally Smith, Kline & French), Approved (1970)) and Divalproex sodium / Valproate (AbbVie, Approved (1995 for acute mania)). First-line treatment consists of oral mood stabilizers and second-generation atypical antipsychotics.
Competition sources
Sources: bbrfoundation.org · innovationscns.com · neiglobal.com · drugtopics.com · wikipedia.org · veeva.com · veeva.com · veeva.com
Why it could work. Sparing non-target brain regions avoids the sedation and metabolic weight gain of antipsychotics, following an 80% median reduction in long seizure episodes in Phase 2a epilepsy.
Why it could fail. Complex psychiatric manic circuits may not translate from focal seizure suppression, and undefined Phase 2 trial controls risk high placebo response.
EIKN — Eikon Therapeutics
CATALYST Oct 23, 2026Conference | RANK 80 | PRICE $8.95 -17% 20d |
| CAP $485M (54M sh) | CASH $473M ~22 mo | |
Eikon Therapeutics will present Phase 1/2 clinical data for EIK1003 in advanced solid tumors on Oct 23, 2026, at the ESMO Congress in Madrid. The presentation decides whether next-generation PARP1 selectivity enables tolerable combination regimens alongside standard chemotherapies.
Company. Eikon Therapeutics is a clinical-stage oncology company discovering targeted small molecules. It generates no product revenue, financing multi-candidate Phase 1/2 clinical programs including EIK1001, EIK1003, and EIK1004 from cash reserves raised in its 2026 IPO.
Science & competition. EIK1003 selectively inhibits and traps PARP1 to disrupt DNA damage repair while sparing PARP2, aiming to minimize dose-limiting bone marrow suppression. Rivals include Olaparib (AstraZeneca / Merck, FDA-approved) and Saruparib (AstraZeneca, Phase 3). The standard of care is platinum-based chemotherapy and first-generation dual PARP1/2 inhibitors.
Competition sources
Sources: asco.org · eikontx.com · onclive.com · fiercebiotech.com · investing.com · frontiersin.org · nih.gov · delveinsight.com
Why it could work. Spared PARP2 activity could allow full therapeutic doses alongside paclitaxel or abiraterone without severe overlapping bone marrow suppression.
Why it could fail. Combining targeted agents with cytotoxic chemotherapy frequently triggers dose-limiting neutropenia or neuropathy, forcing dose reductions that dilute tumor responses.
PALI — Palisade Bio
CATALYST Oct 9–Oct 14, 2026Conference | RANK 80 | PRICE $1.59 -23% 20d |
| CAP $277M (174M sh) | CASH $121M ~80 mo | |
Palisade Bio will present clinical data for PALI-2108 at the ACG Annual Scientific Meeting between Oct 9–Oct 14, 2026. The presentation decides whether gut-restricted prodrug cleavage maintains mucosal healing without typical PDE4 emetic toxicity.
Company. Palisade Bio is a clinical-stage biopharmaceutical company developing localized oral prodrugs for inflammatory bowel disease. It generates no commercial revenue, deploying its cash balance toward Phase 2 ASCENTRA trials in ulcerative colitis and Crohn's disease.
Science & competition. PALI-2108 is an oral prodrug that cleaves locally in the ileum and colon into an active PDE4 inhibitor, reducing mucosal inflammation while minimizing systemic exposure. Rivals include Tofacitinib (Xeljanz) (Pfizer, Approved: 2018) and Upadacitinib (Rinvoq) (AbbVie, Approved: 2022). The standard of care is oral 5-aminosalicylates with corticosteroids, followed by biologics or targeted oral small molecules.
Competition sources
Sources: palisadebio.com · clinicaltrials.gov · allclinicaltrials.com · nih.gov · oup.com · nih.gov · appliedclinicaltrialsonline.com · delveinsight.com
Why it could work. Localized gut release avoids systemic PDE4-mediated emesis, building on prelimi
Read more
BIOTECH CATALYST AI SCANNER — October WK
BIOSTOCKINFO / CATALYST SCANNER Scan date 2026-10-12 · 10 featured · 10 watchlist The tape XBI closed October 9 at 153.77, slipping 0.4% over one week, 3.5% over one month, and 3.3% over three months, while maintaining a 26.5% gain year to date and sitting 9.
MLTX, AVTX, ZURA vs. ABBV: The Hidradenitis Suppurativa Race Hinges on One Readout
AbbVie's lutikizumab readout is the next big test for MLTX, AVTX and ZURA. A side-by-side look at HS efficacy, safety and dosing, Merck's new data, and how I'm playing it.
BIOTECH CATALYST AI SCANNER — October WK2
BIOSTOCKINFO / CATALYST SCANNER Scan date 2026-10-03 · 10 featured · 10 watchlist The tape The SPDR S&P Biotech ETF (XBI) closed at 154.43 on October 2, down 0.4% over one week, down 6.6% over one month, down 3.8% over three months, up 27.1%
BIOTECH CATALYST AI SCANNER — October WK1
I’ve been travelling for over a week, with the calendar running autonomously while I’ve been away. I managed to put together the October Week 1 Scanner remotely, but haven’t been able to personally cross-check every detail before publication. Please verify key information against the original sources.